Tin t&#x1EE9;c &amp; C&#x1EAD;p nh&#x1EAD;t

Intensifying the dose of ustekinumab to 4- or 6-weekly is a common recourse among Crohn’s disease (CD) patients, a recent study has found. Patients who had failed prior therapies are more likely to see such intensification.

One in three Crohn’s disease patients undergo ustekinumab dose intensification

Lidocaine outperforms amiodarone for in-hospital cardiac arrest

In the treatment of adult patients with in-hospital cardiac arrest, lidocaine appears to result in more favourable survival and neurological outcomes as compared with amiodarone, a study has shown.

Lidocaine outperforms amiodarone for in-hospital cardiac arrest

ICD therapy feasible in vasospastic angina after resuscitation

Using implantable cardioverter defibrillator (ICD) as a secondary prophylaxis is feasible in patients resuscitated from sudden cardiac arrest (SCA), leading to similar long-term outcomes in those with vasospastic angina (VSA) or other cardiac diseases, a recent study has found.

ICD therapy feasible in vasospastic angina after resuscitation

COSMIC-313: Adding cabozantinib to nivo-ipi may improve PFS in advanced RCC

The combination of nivolumab, ipilimumab, and cabozantinib improved progression-free survival (PFS) in patients with previously untreated, advanced renal cell carcinoma (RCC) of intermediate or poor risk as per IMDC* criteria, results of the phase III COSMIC-313 trial showed.

COSMIC-313: Adding cabozantinib to nivo-ipi may improve PFS in advanced RCC

04 Nov 2022

Atezolizumab–bevacizumab combo shows therapeutic potential in advanced mucosal melanoma

The combination of atezolizumab plus bevacizumab demonstrates promising antitumour activity in patients with advanced mucosal melanoma while having a manageable safety profile, according to the results of a phase II study.

Atezolizumab–bevacizumab combo shows therapeutic potential in advanced mucosal melanoma

Once-a-day pill as switch option receives thumbs up across multiple HIV populations

Switching to the once-a-day, fixed-dose pill that contains bictegravir, emtricitabine, and tenofovir (BIC/FTC/TAF) appears to be safe and effective in older HIV patients and in people living with HIV (PLHIV) with pretreatment or treatment-acquired resistance, in addition to yielding metabolic benefits, according to studies presented at HIV Glasgow 2022.

Once-a-day pill as switch option receives thumbs up across multiple HIV populations

04 Nov 2022

Alcohol benefits may be overestimated

The benefits of alcohol for cardiovascular disease (CVD) outcomes may have been overestimated by observational studies, according to a recent analysis.

Alcohol benefits may be overestimated

04 Nov 2022

Detectable viral loads persist in one-third of PLHIV in Asia-Pacific region

Between 2015 and 2020, nearly a third of people living with HIV (PLHIV) in Asia-Pacific countries still show a detectable viral load, according to a study presented at the HIV Glasgow 2022 Congress.

Detectable viral loads persist in one-third of PLHIV in Asia-Pacific region

04 Nov 2022

Extrapulmonary manifestations of telomere syndrome tied to shorter survival in IPF

Patients with idiopathic pulmonary fibrosis (IPF) who have extrapulmonary manifestations of a telomere syndrome show a decreased survival, according to a recent study.

Extrapulmonary manifestations of telomere syndrome tied to shorter survival in IPF

04 Nov 2022

Small-volume eye drop device on par with SOC in kids

A commercially available eye drop adapter device, dubbed the Nanodropper, results in comparable pupil diameter as standard of care (SOC) for routine pupillary dilation in paediatric patients, according to a recent study.

Small-volume eye drop device on par with SOC in kids